library.onepin.app/estradiol-transdermal-patch Peptide Education Library
OnePin Peptide Library
Education only, not medical advice◆ 21+◆ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Hormonal

Hormonal Hormone replacement therapy Prescription drug

Estradiol Transdermal Patch

Estrogen Patch · Estradiol Patch · Vivelle-Dot

Hormone replacement therapySteroid hormoneEstrogen

Estradiol transdermal patches deliver 17-beta-estradiol through the skin at a controlled rate, bypassing hepatic first-pass metabolism. This route produces steadier serum levels than oral estradiol and avoids the spike in clotting factors seen with oral estrogen. Twice-weekly cadence (every 3-4 days) is standard for most matrix-type patches (Vivelle-Dot, Minivelle, generic estradiol). Strengths from 0.025 mg/day to 0.1 mg/day cover the typical menopausal hormone therapy range. In women with an intact uterus, estradiol MUST be combined with a progestogen to oppose endometrial proliferation.

Quick Start
Route
Transdermal Patch
Start low
0.0375 mg/day patch (mid-low starting dose)
Frequency
Twice weekly (change every 3-4 days)
Timing
Anytime

Apply to clean dry skin on lower abdomen or buttocks. Rotate sites.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
0.0375 mg/day patch (mid-low starting dose) · Transdermal Patch · Twice weekly (change every 3-4 days)
Lowest starting point. Hold about a week to assess tolerance before stepping up.
0.0375 mg/day patch (mid-low starting dose)
Twice weekly (change every 3-4 days)
Standard
Female Hormone Replacement
0.05-0.1 mg/day · Topical · Weekly
human clinical trial · FDA Climara label
0.05-0.1 mg/day
Weekly
◆
01

How it works

17-beta-estradiol binds intracellular estrogen receptors (ER-alpha and ER-beta) in target tissues. Receptor-ligand complexes translocate to the nucleus and act as transcription factors at estrogen response elements (EREs), modulating expression of hundreds of genes. Transdermal delivery avoids first-pass hepatic metabolism, producing roughly 3x higher bioavailability than oral estradiol and minimizing hepatic synthesis of clotting factors, SHBG, and triglycerides. Steady-state serum estradiol of 40-100 pg/mL is typical on mid-range patches.

17-beta-estradiol binds intracellular estrogen receptors (ER-alpha and ER-beta) in target tissues. Receptor-ligand complexes translocate to the nucleus and act as transcription factors at estrogen response elements (EREs), modulating expression of hundreds of genes. Transdermal delivery avoids first-pass hepatic metabolism, producing roughly 3x higher bioavailability than oral estradiol and minimizing hepatic synthesis of clotting factors, SHBG, and triglycerides. Steady-state serum estradiol of 40-100 pg/mL is typical on mid-range patches.

02

What to expect

Early
Days 1–7

1-2 weeks: vasomotor symptom reduction begins

03

Evidence

HumanPresent
AnimalPresent
In-vitroPresent
2000Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints · von Holst T, Salbach B, Maturitas ↗peer reviewed
2002Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial · Cooper C, Stakkestad JA, Radowicki S, et al, Osteoporosis International ↗peer reviewed
2002Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches · Reginster JY, Albert A, Deroisy R, et al, Climacteric ↗peer reviewed
2023Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review · Vinogradova Y, Coupland C, Hippisley-Cox J, et al, Climacteric ↗review
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

Thyroid replacementCompatible but estrogen raises TBG - free T4 may drop; monitor TSH after starting.
Testosterone (low-dose female HRT)Commonly paired in female HRT for energy, libido, and body composition benefits.
ProgesteroneRequired adjunct in women with a uterus to prevent endometrial hyperplasia.

Keep separate

Combined hormonal contraceptivesAdditive estrogen exposure raises thrombosis risk - do not stack.
Anastrozole / LetrozoleAromatase inhibitors directly oppose estradiol replacement. Only combined under specialist direction.
05

Side effects & safety

Commonly reported

  • Application site reaction
  • Breast tenderness
  • Headache
  • Nausea
  • Water retention

Less common & notes

  • Unscheduled bleeding
  • Mood changes
  • Libido changes
  • Melasma
06

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~4 hours after patch removal
Peak · Tmax
Steady state by day 2-3 of continuous wear
Elimination
Detectable serum levels 24-48 hours after removal
Activity
3-4 days per patch (twice-weekly cadence)

Storage. Store pouched patches at controlled room temperature (20-25C / 68-77F). Do not store unpouched. Keep away from direct sunlight and heat sources. Apply immediately upon opening pouch.

07

Regulatory status

FDA-approved for menopausal symptoms, osteoporosis prevention, and hypogonadism. Prescription-only. Black-box warning on WHI-associated risks (VTE, stroke, breast cancer). Matrix-type patches are NOT cuttable per FDA label.

Put it to work

Calculate, log & track

Open Estradiol Transdermal Patch straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Estradiol Transdermal Patch in the app →

Go deeper

The guide & community

The complete Estradiol Transdermal Patch walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community